Clinical trial Recruiting at 1 site Observational Ages 18 and up

Assessing cannabis treatment for cancer patients undergoing immunotherapy

Official title: Assessing Benefits and Harms of Cannabis Use in Patients Treated With Immunotherapy for Cancer: a Prospective Cohort Study

Run by State University of New York at Buffalo · NCT06206941 · Data updated 2026-11-12

This study is testing how cannabis use affects symptoms in cancer patients receiving immunotherapy to see if it helps them feel better.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment450 (estimated)
SponsorState University of New York at Buffalo
Academic / other
Drugs / interventionsimmunotherapy
Locations2 sites (Portland, Oregon and 1 other locations)
StatusRecruiting
StartedJanuary 2, 2025
Main results expectedSeptember 30, 2027
Study endsDecember 31, 2027
Registry record updatedAugust 26, 2026
Trial IDNCT06206941 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 21 and older with a cancer diagnosis who are planning to or currently receiving immunotherapy treatment.

Probably not a fit

Patients who have used synthetic cannabis or only Cannabidiol (CBD), or those with severe pain limiting movement, may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate how cancer patients treated with immune checkpoint inhibitors manage symptoms related to their condition and treatment, including the use of cannabis. Participants will complete online surveys and ecological momentary assessments at various time points over a year to compare symptoms between cannabis users and non-users. The study will recruit participants through institutional registries, electronic medical records, and direct outreach during outpatient visits. Data will be collected via video or phone calls to ensure convenience and accuracy.

Why it matters

Potential benefit: If successful, this study could enhance understanding of symptom management in cancer patients, potentially leading to improved patient care and safety.

How similar studies have gone: While the use of cannabis in symptom management for cancer patients is being explored, this specific approach assessing its impact alongside immunotherapy is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* adult age of 18 years or older
* cancer diagnosis and planning or using immunotherapy treatment,
* pain and spend less than 50% in bed or chair
* fluent in english language

Exclusion Criteria:

* use synthetic cannabis or only use Cannabidiol (CBD)
* non users but used in the past 3 months
* Patients receiving immunosuppressants or organ transplant recipients.
* Patients within 6 months of Hospice care.
* Pain that limits movement to more than 50% of their day in bed or chair

Where it's running

  • Thomas Jefferson University
    Philadelphia, Pennsylvania, United States
    Recruiting
  • Oregon Health and Science University
    Portland, Oregon, United States
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.